GNPX - Genprex, Inc.
IEX Last Trade
0.92
0.045 4.870%
Share volume: 100
Last Updated: Thu 26 Dec 2024 04:20:38 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
4.47%
PREVIOUS CLOSE
CHG
CHG%
$0.88
0.04
5.12%
Fundamental analysis
18%
Profitability
25%
Dept financing
3%
Liquidity
75%
Performance
0%
Performance
5 Days
2.00%
1 Month
-7.18%
3 Months
164.97%
6 Months
-54.50%
1 Year
337.62%
2 Year
-7.18%
Key data
Stock price
$0.92
DAY RANGE
$0.88 - $0.88
52 WEEK RANGE
$0.24 - $14.40
52 WEEK CHANGE
-$89.33
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: J. Rodney Varner
Region: US
Website: genprex.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: genprex.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes.
Recent news